Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted February 03, 2025
Four Male Enhancement and Energy Supplements Found to Contain Drugs
On January 16, 2025, the FDA issued a Warning Letter to Mihon Corp. d/b/a VitalityVita and Boulla, LLC after FDA analysis found four of the company’s supplements, VitalityXtra, PeakMax, ZapMax, and ZoomMax, to contain undeclared sildenafil. In addition, PeakMax, ZapMax, and ZoomMax were found to contain undeclared diclofenac.
(See ConsumerLab's Sexual Enhancer Supplements Review for tests of related products.)
Sildenafil (the active ingredient in Viagra) may cause symptoms like headache and flushing and can interact with medications containing nitrates such as nitroglycerine, resulting in dangerously low blood pressure.
Diclofenac is a prescription non-steroidal anti-inflammatory drug (NSAID) that can cause serious cardiovascular events such as heart attack or stroke, as well as bleeding, ulceration, and fatal tears of the stomach and intestines, or liver toxicity. Diclofenac may also interact with other medications and significantly increase the risk of adverse events.
VitalityXtra, PeakMax, ZapMax, and ZoomMax were promoted to increase energy, endurance, stamina and/or strength and were sold on the company’s website, as well as on the company’s Amazon storefront.
Mihon Corp. d/b/a VitalityVita and Boulla, LLC must respond to the FDA in writing within 15 days of receipt of the warning explaining the steps it has taken to address these violations.
For more information, use the links below.
Mihon Corp. d/b/a VitalityVita and Boulla, LLC
See related recalls and warnings:
Sexual Enhancement Supplements Sold on Amazon Recalled
Two Sexual Enhancement Supplements Sold on Amazon Recalled
Three Male Enhancement Products Recalled Due to Undeclared Drugs
Three Sexual Enhancement Supplements Sold on Amazon Recalled
Eleven Brands of Sexual Enhancement Supplements Recalled Due to Undeclared Prescription Drugs